Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate

NCT ID: NCT00489840

Last Updated: 2012-10-25

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 5 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-05-31

Brief Summary

Investigation to evaluate Anecortave Acetate in the treatment of chronic central serous chorioretinopathy

Detailed Description

Central serous chorioretinopathy (CSC) is a disease of the macula characterized by loss of vision from exudation of fluid under the retina localized to the posterior pole. Acute central serous chorioretinopathy (CSC) has been defined as an idiopathic detachment of the neurosensory retina in the macular region associated with a focal leak at the level of the retinal pigment epithelium on fluorescein angiography. This area of leakage usually corresponds to a defect in retinal pigment epithelium (RPE). An acute episode of CSC usually resolves within 3 months from the time of onset with almost total restoration of the visual acuity.

However, in a more severe form of the disease, chronic central serous chorioretinopathy, there is diffuse decompensation of the RPE, recurrent retinal detachments, and progressive loss of visual acuity. Indocyanine green angiography shows diffuse hyperpermeability of the choriocapillaris layer. This chronic form of CSC is usually bilateral, and often causes severe vision loss and impaired quality of life for the patient. Chronic central serous chorioretinopathy can be defined on the basis of two factors: 1) persistence of the detachment for more than 6 months and 2) chronic recurrent acute detachments with widespread decompensation of the retinal pigment epithelium.

The standard of care for acute CSC is observation for a period of up to 3 months. If there is no complete resolution of the retinal detachment by 3 months, focal laser photocoagulation therapy may be used to treat the area of leakage. This treatment is usually effective in stopping leakage of fluid under the retina and causing resolution of the detachment. However, laser photocoagulation therapy is not beneficial in the treatment of chronic CSC because there is not a single easily identifiable point of leakage but rather diffuse disease of the RPE, thus rendering laser treatment ineffective. Because of the limitations of laser photocoagulation for chronic CSC, other treatments are currently under evaluation.

Corticosteroids appear to be intimately related to the pathogenesis of the disease. Exogenous corticosteroids have been shown to induce the disease via a variety of routes, whether oral, intravenous, intranasal, or intraarticular. Secondly, patients with endogenous hypercortisolism, such as those with Cushing's syndrome or with a type A personality, are also at increased risk of developing the disease.

The purpose of this medical research study is to evaluate Anecortave Acetate as an approach which may benefit patients with chronic CSC. Anecortave acetate is a novel agent, derived from the steroid cortisone, but modified to eliminate glucocorticoid effects via removal of the 11β-hydroxyl group, addition of a double bond at C9-11, and addition of an acetate group at C21 to increase ocular penetration and stability. Anecortave acetate has recently been shown to possess anti-glucocorticoid effects in the eye, such as in blocking steroid-induced glaucoma. Anecortave acetate treatment to the eye has been evaluated for other disorders, such as macular degneration, and boasts an outstanding safety record, with no adverse systemic reactions. Ocular adverse events were mild, such as subconjunctival hemorrhage.

The concept of this protocol is that if Anecortave Acetate blocks the steroid receptors for glaucoma and prevents steroid-induced glaucoma, perhaps it blocks the the steroid induced receptors involved in the pathogenesis of central serous chorioretinopathy. If successful, this modality of treatment may reduce the risk of progressive visual damage due to chronic CSC and perhaps even improve visual function without causing destruction to the overlying neurosensory retina.

Conditions

Chronic Central Serous Chorioretinopathy

Keywords

Chronic Central Serous Chorioretinopathy

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

anecortave acetate

Group Type: EXPERIMENTAL

Anecortave Acetate Sterile suspension 15 mg

Intervention Type: DRUG

anecortave acetate sterile suspension 15 mg., juxtascleral injection, every 6 months. for 24 months

Anecortave Acetate

Intervention Type: DRUG

anecortave acetate suspension 15 mg. juxtascleral injection every 6 months for 24 months.

Interventions

Anecortave Acetate Sterile suspension 15 mg

anecortave acetate sterile suspension 15 mg., juxtascleral injection, every 6 months. for 24 months

Intervention Type: DRUG

Anecortave Acetate

anecortave acetate suspension 15 mg. juxtascleral injection every 6 months for 24 months.

Intervention Type: DRUG

Other Intervention Names

retaane; retaane

Eligibility Criteria

Inclusion Criteria

1. A male or female, of any race with clinical signs of chronic CSC:Evidence of chronic central serous chorioretinopathy and clinical/angiographic findings typical of the disease of greater than 6 months duration. Chronic central serous chorioretinopathy can be defined on the basis of two factors: 1) persistence of the detachment for more than 6 months and 2) chronic recurrent acute detachments with widespread decompensation of the retinal pigment epithelium

2. Patient must have best corrected ETDRS visual acuity between 20/40 and 20/320 in the Study Eye and visual acuity of 20/800 or better Fellow Eye

3. Patient must be willing, able to comply with the protocol, and provide informed consent.

Exclusion Criteria

1. Patient with tears in retinal pigment epithelium.

2. Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions.

3. Patients who have undergone intraocular surgery within last 2 months or capsulotomy within last month in study eye

4. Patient participating in any other investigational drug study.

5. Inability to obtain photographs to document CNV (including difficulty with venous access)

6. Patient with significant liver disease or uremia.

7. Patient with known adverse reaction to indocyanine green or iodine.

8. Patient is pregnant or nursing.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

LuEsther T. Mertz Retinal Research Center

OTHER

Sponsor Role: collaborator

Alcon Research

INDUSTRY

Sponsor Role: collaborator

Manhattan Eye, Ear & Throat Hospital

OTHER

Sponsor Role: lead

Responsible Party

Joan

Lawrence A. Yannuzzi, M.D.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Lawrence A. Yannuzzi, MD

Role: PRINCIPAL_INVESTIGATOR

Manhattan Eye, Ear & Throat Hospital

Locations

Manhattan Eye, ear & Throat Institute

New York, New York, United States

Vitreous-Retina-Macula Consultants of New York,PC

New York, New York, United States

Countries

United States

Other Identifiers

CSC-AA

Identifier Type: -

Identifier Source: org_study_id